Food News and Research

RSS

Sustamine L-Alanyl-L-Glutamine supplement increases performance in endurance exercise and activity

A clinical study by Dr. Jay Hoffman, PhD, professor and chair of the Department of Health and Exercise Science at the College of New Jersey, has shown Sustamine™ L-Alanyl-L-Glutamine, increases performance in endurance exercise and activity. The study was published on February 3, 2010, in the Journal of the International Society of Sports Nutrition (JISSN), a peer-reviewed journal covering various aspects of sports nutrition, supplementation, exercise metabolism, and/or scientific policies related to sports nutrition.

12 Feb 2010

Heavy rains hit tent camps in Haiti

Heavy rains hit earthquake survivors in tent camps in Port-au-Prince on Thursday, "bringing a warning of fresh misery to come for the 1 million people living on the streets," Reuters reports.

12 Feb 2010

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, announced today that it has begun distributing and selling Cobroxin through mass food and drug retail chains in the Northeast, Southeast, Middle Atlantic and Midwest regions.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

Study could lead to new ways to combat obesity

The tiny tongue of a fruit fly could provide big answers to questions about human eating habits, possibly even leading to new ways to treat obesity, according to a study from a team of Texas A&M University researchers.

12 Feb 2010

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).

12 Feb 2010

British rhubarb could be a potential source of anti-cancer agent

Eating rhubarb baked in a crumble is not only tasty it may also be the best way to take advantage of its health benefits, and could lead to the development of new cancer treatments.

From Sheffield Hallam University 11 Feb 2010

Coalition group calls for bigger FDA budget

The Los Angeles Times reports that when the president's budget was announced, calling for an increase in the FDA's budget, "a coalition of public interest advocates, patient groups and healthcare industry interests regulated by the FDA had a swift response: It's not enough. 'We are disappointed in the president's budget request and ... will seek to increase' the budget, said Steven Grossman, deputy executive director of Alliance for a Stronger FDA.

11 Feb 2010

Calif. budget cuts will hit adult day care centers, prison health care; Texas and Kansas weigh Medicaid cuts

Under the most recent cost-saving budget proposals, 327 adult day healthcare centers throughout California would be eliminated. Cuts could save the state $135 million in fiscal 2011, state projections show.

11 Feb 2010

FDA grants approval for Abbott's antiretroviral medication Norvir

Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.

11 Feb 2010

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

11 Feb 2010

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.

11 Feb 2010

Cambridge Heart submits 510(k) application for Microvolt T-wave Alternans OEM Module

Cambridge Heart, Inc., today announced that the Company has completed the development phase of its Microvolt T-wave Alternans (MTWA) OEM Module, and has submitted a 510(k) application for regulatory approval with the U.S. Food and Drug Administration (FDA). The module is the centerpiece of the Company’s new business model that involves partnering with leading stress test equipment manufacturers to broaden the distribution and use of MTWA technology.

11 Feb 2010

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for intravenous (IV) acetaminophen.

11 Feb 2010

Microbial risk management in food processing needs to be improved within EU countries

Microbial risk management is difficult and very important in food processing and although we have common EU legislation for food producers microbial risk management needs to be improved and harmonized within EU countries. Microbial risk management consists of several parts. Knowledge of hygienic design and factory layout can prevent severe microbial hazards.

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

First Edition: February 11, 2010

Today's headlines raise interesting questions for health reform, including whether Sen. Judd Gregg can play an important role in finding bipartisanship.

11 Feb 2010

Seminar held in Tallinn provides information about hygienic design and cleaning procedures

Hygiene in food processing factories is highly dependent on hygienic design of the process lines and equipment as well as on cleaning efficiency. Principles of hygiene design are simple but several faults appear in food processing premises. Hygienically designed process lines are supposed to be cleanable but still optimization of cleaning programs is worthwhile.

11 Feb 2010

DuPont Agriculture & Nutrition segment expected to grow by 10% in 2010, says James C. Borel

DuPont Executive Vice President James C. Borel said he expects the DuPont Agriculture & Nutrition segment to grow sales by 10 percent in 2010 and increase pre-tax operating income margin across the seed, crop protection, and nutrition and health businesses.

11 Feb 2010

Nontraditional companies to help reshape healthcare marketplace

Information technology (IT) companies, large retailers, and telecommunication firms are strategically poised to capitalize on rapid changes taking place in health care, and pharmaceutical companies are increasingly looking for innovative ways to collaborate with these new players to reach and improve outcomes for patients.

11 Feb 2010

Food News and Research

Sustamine L-Alanyl-L-Glutamine supplement increases performance in endurance exercise and activity

Heavy rains hit tent camps in Haiti

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Study could lead to new ways to combat obesity

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

British rhubarb could be a potential source of anti-cancer agent

Coalition group calls for bigger FDA budget

Calif. budget cuts will hit adult day care centers, prison health care; Texas and Kansas weigh Medicaid cuts

FDA grants approval for Abbott's antiretroviral medication Norvir

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Cambridge Heart submits 510(k) application for Microvolt T-wave Alternans OEM Module

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Microbial risk management in food processing needs to be improved within EU countries

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

First Edition: February 11, 2010

Seminar held in Tallinn provides information about hygienic design and cleaning procedures

DuPont Agriculture & Nutrition segment expected to grow by 10% in 2010, says James C. Borel

Nontraditional companies to help reshape healthcare marketplace

The future is bioengineered: Synthetic biology and global sustainability eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News